We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov Menu

DAHANCA 19: The Importance of the EGFr-inhibitor Zalutumumab for the Outcome After Curative Radiotherapy for HNSCC

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00496652
Recruitment Status : Completed
First Posted : July 4, 2007
Last Update Posted : November 25, 2016
Information provided by (Responsible Party):
Danish Head and Neck Cancer Group

No Study Results Posted on ClinicalTrials.gov for this Study
  Recruitment Status : Completed
  Primary Completion Date : July 2012
  Study Completion Date : November 2016